GlassScriptPhysician profile
Aracelis Silva
NPI 1366841884
$5,274.17
in general payments reported to CMS, 2019-2025
21 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $846 · 2023: $1,067 · 2024: $1,499 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,189 · Education: $38.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,189.28 |
| Education | $38.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,300.58 | 2022-2025 | Krystexxa, Evenity, Tavneos |
| Abbvie INC. | $910.57 | 2022-2025 | |
| Janssen Biotech, INC. | $555.52 | 2022-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $433.66 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $315.20 | 2023-2025 | Saphnelo |
| Pfizer INC. | $310.38 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $252.66 | 2024-2025 | Tremfya |
| Horizon Therapeutics Plc | $250.57 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.80 | 2022-2025 | Ofev, Cyltezo |
| Ucb, INC. | $176.06 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $83.08 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $70.20 | 2023-2024 | Opsumit |
| Genentech USA, INC. | $59.42 | 2022-2025 | Gazyva |
| Sobi, INC | $59.17 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $56.74 | 2024 | Idacio, Tyenne |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.38 | 2025 | Orencia |
| Lilly USA, LLC | $41.78 | 2022-2024 | Taltz |
| Sandoz INC. | $39.99 | 2024-2025 | Jubbonti, Hyrimoz |
| Vertex Pharmaceuticals Incorporated | $32.52 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.89 | 2022 | |
| Octapharma USA, INC. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aracelis Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.